153 related articles for article (PubMed ID: 9364657)
1. The molecular genetics of pancreatic cancer.
Howe JR; Conlon KC
Surg Oncol; 1997; 6(1):1-18. PubMed ID: 9364657
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathobiology of pancreatic adenocarcinoma.
Mangray S; King TC
Front Biosci; 1998 Nov; 3():D1148-60. PubMed ID: 9820739
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
4. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
5. [Molecular diagnosis of pancreatic cancer].
Sugano K
Nihon Geka Gakkai Zasshi; 1997 Jul; 98(7):597-603. PubMed ID: 9276865
[TBL] [Abstract][Full Text] [Related]
6. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in gene change of pancreatic cancer].
Wang YY; Cui QC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):79-82. PubMed ID: 15052782
[TBL] [Abstract][Full Text] [Related]
8. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
9. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis.
Löhr M; Müller P; Mora J; Brinkmann B; Ostwald C; Farré A; Lluis F; Adam U; Stubbe J; Plath F; Nizze H; Hopt UT; Barten M; Capellá G; Liebe S
Gastrointest Endosc; 2001 Jun; 53(7):734-43. PubMed ID: 11375580
[TBL] [Abstract][Full Text] [Related]
10. The genetics of pancreatic cancer.
Cowgill SM; Muscarella P
Am J Surg; 2003 Sep; 186(3):279-86. PubMed ID: 12946833
[TBL] [Abstract][Full Text] [Related]
11. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
[TBL] [Abstract][Full Text] [Related]
12. Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.
Soliman AS; Bondy M; Webb CR; Schottenfeld D; Bonner J; El-Ghawalby N; Soultan A; Abdel-Wahab M; Fathy O; Ebidi G; Zhang Q; Greenson JK; Abbruzzese JL; Hamilton SR
Int J Cancer; 2006 Sep; 119(6):1455-61. PubMed ID: 16619252
[TBL] [Abstract][Full Text] [Related]
13. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
[TBL] [Abstract][Full Text] [Related]
14. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
15. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool.
Mulcahy H; Farthing MJ
Ann Oncol; 1999; 10 Suppl 4():114-7. PubMed ID: 10436800
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
19. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
20. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
Hayashi N; Egami H; Ogawa M
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
